Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases (ESSAi)

Toulouse University Hospital

Status: Enrolling

Conditions: Myositis; Scleroderma; Vasculitis; Inflammatory Bowel Diseases; Lupus Erythematosus

Treatments: Biological: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT05251415

RC31/21/0505

Details and patient eligibility

About

The aim of this project is to start a biological and clinical collection of patients presenting systemic autoimmune disease. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies

Full description

Autoimmune diseases group together less than a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.

Enrollment: 3,000 estimated patients

Sex: All

Ages: 6 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with rare systemic autoimmune diseases (lupus, scleroderma, myositis for example),
• Patients with atypical presentations of documented or probable systemic autoimmune diseases,
• Patients receiving, or likely to receive new, innovative therapies (new molecule on the market, gene therapy, cell therapy, etc.).

Exclusion criteria

• Known anemia and hemoglobin <10 g / dl
• Patients under protective supervision (guardianship, curators)
• Pregnant or breastfeeding woman

Trial design

3,000 participants in 1 patient group

patients suffering from autoimmune disease

Description:

Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity.

Treatment:

Biological: Blood sampling